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Abstract
Background: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders
worldwide. Antidepressants are frequently used to treat major depressive disorder. It has been shown repeatedly
that antidepressants seem to reduce depressive symptoms with a statistically significant effect, but the clinical
importance of the effect sizes seems questionable. Both beneficial and harmful effects of antidepressants have not
previously been sufficiently assessed. The main objective of this review will be to evaluate the beneficial and
harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major
depressive disorder.
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Methods/design: A systematic review with meta-analysis will be reported as recommended by Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA), bias will be assessed with the Cochrane Risk of Bias tool-
version 2 (ROB2), our eight-step procedure will be used to assess if the thresholds for clinical significance are
crossed, Trial Sequential Analysis will be conducted to control for random errors, and the certainty of the evidence
will be assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach. To identify relevant trials, we will search both for published and unpublished trials in major medical
databases from their inception to the present. Clinical study reports will be obtained from regulatory authorities
and pharmaceutical companies. Two review authors will independently screen the results of the literature searches,
extract data, and perform risk of bias assessment. We will include any published or unpublished randomised clinical
trial comparing one or more antidepressants with placebo, ‘active placebo’, or no intervention for adults with major
depressive disorder. The following active agents will be included: agomelatine, amineptine, amitriptyline, bupropion,
butriptyline, cianopramine, citalopram, clomipramine, dapoxetine, demexiptiline, desipramine, desvenlafaxine,
dibenzepin, dosulepin, dothiepin, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, iprindole,
levomilnacipran, lofepramine, maprotiline, melitracen, metapramine, milnacipran, mirtazapine, nefazodone,
nortriptyline, noxiptiline, opipramol, paroxetine, protriptyline, quinupramine, reboxetine, sertraline, trazodone,
tianeptine, trimipramine, venlafaxine, vilazodone, and vortioxetine. Primary outcomes will be depressive symptoms,
serious adverse events, and quality of life. Secondary outcomes will be suicide or suicide attempt, suicidal ideation,
and non-serious adverse events.
Discussion: As antidepressants are commonly used to treat major depressive disorder in adults, a systematic review
evaluating their beneficial and harmful effects is urgently needed. This review will inform best practice in treatment
and clinical research of this highly prevalent and burdensome disorder.
Systematic review registration: PROSPERO CRD42020220279
Background
Description of participants
Major depressive disorder is estimated by the World
Health Organization (WHO) to affect more than 264
million people globally, making the disorder one of the
leading causes of disability worldwide [1, 2]. The esti-
mated lifetime prevalence of major depressive disorder is
between 10 and 20% [3, 4]. In 2010, the annual eco-
nomic burden in the USA alone was estimated to exceed
210 billion US dollars including both direct medical
costs and indirect costs related to work ability and co-
morbidities [5]. Major depressive disorder is charac-
terised by depressed mood and loss of interest or
pleasure resulting in significant psychological distress
and functional impairment [6, 7]. Furthermore, risks of
suicides and suicide attempts significantly increases dur-
ing major depressive episodes [8, 9]. Together, these
findings emphasise the need for efficacious and cost-
effective treatments for this burdensome and highly
prevalent psychiatric disorder, especially treatments
where benefits outweigh harms.
Description of interventions
Pharmacotherapy is widely used in the treatment of
major depressive disorder, particularly in the Western
world, but also in several other countries [10, 11]. Data
published in 2017 from the National Health and Nutri-
tion Examination Survey showed that during 2011–2014,
about one in eight people aged 12 and above in the USA
reported taking antidepressants during the previous
month [12]. The use of antidepressants has increased
nearly 65% over a 15-year time frame [12] and more
than 60% of people in the USA taking antidepressants
have been taking them for more than two years [12].
Today, antidepressants for major depressive disorder, ei-
ther alone or in combination with psychotherapy, are
recommended by the UK National Institute for Health
and Care Excellence (NICE) and the American Psychi-
atric Association, as well as different national clinical
guidelines [13–19].
Several different antidepressants exist. Before the late
1980s, pharmacological treatment was limited to tricyclic
antidepressants (TCAs) and monoamine oxidase inhibi-
tors (MAOIs). TCAs and MAOIs are now commonly re-
ferred to as first-generation antidepressants. Now,
second-generation antidepressants comprise most anti-
depressant prescriptions. These drugs include selective
serotonin reuptake inhibitors (SSRIs), serotonin and nor-
epinephrine reuptake inhibitors (SNRIs), and other drugs
with related mechanisms of action that selectively target
neurotransmitters. For an overview of the different types
of antidepressants, please see Table 1 [10, 20, 21].
How the interventions might work
Antidepressants aim to increase the availability of spe-
cific neurotransmitters that are sought to play a role in
the development of major depressive disorder, most
commonly serotonin, noradrenaline, and dopamine. The
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various antidepressants target different neurotransmit-
ters [22]. For example, selective serotonin reuptake in-
hibitors (e.g., citalopram and fluoxetine) specifically
block the reuptake of serotonin, while selective nor-
adrenaline reuptake inhibitors (e.g. reboxetine) specific-
ally block the reuptake of noradrenaline. Some
antidepressants simultaneously block the reuptake of
both serotonin and noradrenaline (e.g. duloxetine and
venlaflaxine) and are commonly referred to as ‘dual-ac-
tion’ drugs. However, it remains unclear exactly how an-
tidepressants work in patients with major depressive
disorder [23, 24]. The ‘monoamine hypothesis’ proposes
that diminished activity of serotonergic, noradrenergic,
and dopaminergic pathways plays a causal role in the
pathophysiology of depression [25–27], but the role of
serotonin in the pathophysiology and treatment of major
depressive disorder is still unclear due to unreliable clin-
ical biochemical findings and the difficulty of relating
changes in serotonin activity to mood state [28].
Why is it important to do this review?
It has been repeatedly shown that antidepressants
seem to reduce depressive symptoms with a statisti-
cally significant effect, but the effect sizes are small
or minimal and without importance to patients [10,
29, 30]. A recent review of both within patient and
between patient anchor-based approaches suggested
that the minimal clinically important difference on
the Hamilton Depression Rating Scale 17 (HDRS-17)
is likely to be in the range from 3 to 5 points [31].
Furthermore, there is inconsistent evidence concern-
ing individual variability in who benefits from antide-
pressants [32, 33]. Considering this inconsistency, one
must still assume that the average effect of antide-
pressants applies also to the individual patient [33,
34]. In addition, quality of life has previously been se-
lectively reported in placebo-controlled trials of anti-
depressants [35]. Therefore, the beneficial effects of
antidepressants are currently unclear.
When establishing evidence for any intervention, the
beneficial and harmful effects must be carefully assessed
[36]. If benefits are small or unimportant, society has
less tolerability of risks of adverse events. Harmful ef-
fects are often insufficiently reported in journal articles
compared to trial registries, causing significant under-
reporting of harms associated with antidepressants [37,
38]. This might be the cause for conflicting evidence on
whether antidepressants may trigger harmful effects in
adults with major depressive disorder [39].
A meta-analysis was published in BMJ in 2009 [40]
assessing the risk of suicidality in randomised clinical tri-
als of antidepressants based on proprietary data submit-
ted to US Food and Drug Administration (FDA). The
meta-analysis included major depressive disorder, other
depression, other psychiatric disorders, and non-
psychiatric disorders. The authors concluded that risk of
suicidality associated with use of antidepressants is
strongly age dependent [40]. For suicidal behaviour or
ideation and for suicidal behaviour only, the respective
odds ratios were 1.62 (95% confidence interval [CI] 0.97
to 2.71) and 2.30 (95% CI 1.04 to 5.09) for participants
aged < 25 years, 0.79 (95% CI 0.64 to 0.98) and 0.87
(95% CI 0.58 to 1.29) for those aged 25 to 64 years, and
0.37 (95% CI 0.18 to 0.76) and 0.06 (95% CI 0.01 to
0.58) for those aged ≥ 65 years. However, these age
group subgroup analyses were not predefined in a regis-
tered or published protocol and should therefore be
interpreted with caution.
In a study by Khan et al. [41], the Integrated Safety
Summary data from approval packets for 14 investiga-
tional antidepressant programmes (1991–2013, 40,857
patients, 10,890 exposure years) were used to calculate
suicides and suicide attempts per 100,000 patient expos-
ure years for antidepressant and placebo treatment
groups separately in patients with major depressive dis-
order. The study concluded that deaths by suicide and
suicide attempts had decreased significantly in clinical
trials assessing the effect of antidepressants following the
Table 1 Types of antidepressants
Classes of antidepressants Examples
Tricyclic antidepressants (TCA) Amineptine, amitriptyline, amoxapine, butriptyline, cianopramine, clomipramine, desipramine, demexiptiline,
dibenzepin, dosulepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, maprotiline, melitracen,
metapramine, nortriptyline, noxiptiline, opipramol, protriptyline, tianeptine, trimipramine, and quinupramine.
Tetracyclic antidepressants (TeCAs) Trazodone
Monoamine oxidase inhibitors (MOI) Isocarboxazid and phenelzine
Selective serotonin reuptake inhibitors
(SSRI)
Citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline
Serotonin-norepinephrine reuptake
inhibitors (SNRI)




Atypical antidepressants Agomelatine, bupropion, mirtazapine, and nefazodone, vilazodone, and vortioxetine
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year 2000 compared to the decade before 2000, and as-
sessments of drug-placebo differences in suicide and sui-
cide attempt rates revealed no significant differences
[41]. However, a reanalysis of the data from this study
found different results [39]. According to the reanalysis,
there were 37 suicides (0.116%) and 206 suicide attempts
(0.713%) in the antidepressant group versus 4 suicides
(0.040%) and 28 suicide attempts (0.300%) in the placebo
group. Thus, the suicide rate was significantly higher in
the antidepressant group than in the placebo group
(odds ratio [OR] 2.83; 95% CI 1.13 to 9.67, p = 0.02).
A large network meta-analysis was published in The
Lancet in 2019 [42]. The authors included placebo-
controlled and head-to-head trials of 21 commonly used
antidepressants [42]. The authors recorded all outcomes
as close to eight weeks as possible, that is, only short-
term results were assessed. In this study, neither serious
nor non-serious adverse events were assessed. Instead,
the authors assessed ‘acceptability’ (treatment discon-
tinuation measured by the proportion of participants
who withdrew for any reason) and the proportion of par-
ticipants who dropped out early because of adverse ef-
fects. But these outcomes are difficult to interpret
clinically; participants might, for example, continue tak-
ing antidepressants even if they experience serious ad-
verse effects.
We previously published a systematic review assessing
the effects of the most commonly used antidepressants,
SSRIs [29]. This review assessed both beneficial and
harmful effects of SSRIs. The results showed that there
was a significant effect of SSRIs on depressive symptoms,
but the effect was of questionable clinical relevance and
comparable to that of the network meta-analysis [42].
Moreover, we found almost no data on suicidal behav-
iour, and SSRIs significantly increased the risk of both
serious and non-serious adverse events [29].
No former review has systematically assessed the bene-
ficial and harmful effects of antidepressants including all
types of antidepressants including both published trials
and unpublished data from clinical study reports. There-
fore, there is an urgent need for such a review. The
present systematic review aims at forming the basis for
evidence-based guideline recommendations for the use
of antidepressants for major depressive disorder taking
bias risks (systematic errors), play of chance (random er-
rors), and certainty of the findings into consideration.
Methods
The present protocol has been registered in the PROS-
PERO database (CRD42020220279) and is reported in
accordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocols (PRISMA-P) statement [43, 44]
(see checklist in Additional file 1).
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials irrespective of
setting, publication status, publication year, and lan-
guage. We will not include quasi-randomised trials,
cluster-randomised trials, or observational studies.
Types of participants
Adults (as defined by trialists) with a primary diagnosis
of major depressive disorder as defined by standardised
diagnostic criteria from either DSM-5 [6], ICD-11 [7], or
earlier versions of these diagnostic manuals. Participants
will be included irrespective of sex and comorbidities.
Types of interventions
As experimental intervention, we will accept the follow-
ing: agomelatine, amineptine, amitriptyline, bupropion,
butriptyline, cianopramine, citalopram, clomipramine,
dapoxetine, demexiptiline, desipramine, desvenlafaxine,
dibenzepin, dosulepin, dothiepin, doxepin, duloxetine,
escitalopram, fluoxetine, fluvoxamine, imipramine, iprin-
dole, levomilnacipran, lofepramine, maprotiline, melitra-
cen, metapramine, milnacipran, mirtazapine,
nefazodone, nortriptyline, noxiptiline, opipramol, parox-
etine, protriptyline, quinupramine, reboxetine, sertraline,
trazodone, tianeptine, trimipramine, venlafaxine, vilazo-
done, and vortioxetine. We will accept any of these anti-
depressants as experimental interventions irrespective of
dose and duration of administration.
As control intervention, we will accept the following:
placebo, ‘active placebo’ (a matching placebo that pro-
duces noticeable adverse effects that may convince the
participant being treated and the blinded outcome asses-
sors that the participants are receiving an active inter-
vention), or no intervention. We will accept any of these
control interventions irrespective of dose and duration
of administration.
Cointerventions
We will accept any cointervention, if the cointervention




1. Depressive symptoms measured on the 17-item or
21-item Hamilton Depression Rating Scale (HDRS)
[45]
2. Proportion of participants with one or more serious
adverse events. We will use the International
Conference on Harmonisation of technical
requirements for registration of pharmaceuticals for
human use—Good Clinical Practice (ICH-GCP)
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definition of a serious adverse event, which is any
untoward medical occurrence that resulted in
death, was life-threatening, required hospitalisation
or prolonging of existing hospitalisation, and re-
sulted in persistent or significant disability or jeo-
pardised the participant [46]. If the trialists do not
use the ICH-GCP definition, we will include the
data if the trialists use the term ‘serious adverse
event.’ If the trialists do not use the ICH-GCP def-
inition nor use the term serious adverse event, then
we will also include the data, if the event clearly ful-
fils the ICH-GCP definition for a serious adverse
event. We will secondly assess each serious adverse
event separately.
3. Quality of life
Secondary outcomes
1. Proportion of participants with either a suicide or a
suicide attempt (as defined by the trialists)
2. Suicidal ideation
3. Proportion of participants with one or more non-
serious adverse events (any adverse event not classi-
fied as serious). We will secondly assess each non-
serious adverse event separately.
Exploratory outcomes
1. Depressive symptoms measured on the
Montgomery-Asberg Depression Rating Scale
(MADRS) [47], the Beck’s Depression Inventory
(BDI) [48], or the 6-item HDRS [49].
2. Proportion of participants in remission (as defined
by trialists)
3. Proportion of participants achieving response (as
defined by trialists)
Assessment time points
We will assess all our outcomes at maximum follow-up.
Search methods for identification of studies
Electronic searches
We will search Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Library, MEDLINE
Ovid, Embase Ovid, Latin American and Caribbean
Health Sciences Literature (LILACS; Bireme), PsycINFO
(EBSCO host), Science Citation Index Expanded (SCI-
EXPANDED; Web of Science), Conference Proceedings
Citation Index—Science (CPCI-S; Web of Science), So-
cial Sciences Citation Index (SSCI; Web of Science),
Conference Proceedings Citation Index—Social Science
& Humanities (CPCI-SSH; Web of Science), Chinese
Biomedical Literature Database (CBM), China Network
Knowledge Information (CNKI), Chinese Science Journal
Database (VIP), and Wafang Database to identify rele-
vant trials. We will search all databases from their incep-
tion to the present. For a detailed search strategy for all
electronic databases, see Additional file 2. The search
strategies for the Chinese databases will be given at re-
view stage. Trials will be included irrespective of lan-
guage, publication status, publication year, and
publication type.
Searching other resources
We will include the data from a recent systematic re-
view on 21 antidepressants by Cipriani et al. [42].
The authors of this comprehensive review made the
data available in a public repository. This is the lar-
gest database of new-generation antidepressants for
the acute treatment of major depressive disorder
compiled so far. Further, the reference lists of rele-
vant publications will be checked for any unidentified
randomised trials. We will contact the authors of in-
cluded trials by email asking for unpublished rando-
mised trials. To identify unpublished trials, we will
also search clinical trial registers, websites of pharma-
ceutical companies, websites of US Food and Drug
Administration (FDA), and European Medicines
Agency (EMA). We will request FDA, EMA, and na-
tional medicines agencies to provide all publicly re-
leasable information about relevant randomised
clinical trials of antidepressants that were submitted
for marketing approval, including clinical study re-
ports [50]. Additionally, we will hand search confer-
ence abstracts from psychiatry conferences for
relevant trials. We will also include unpublished and
grey literature trials if we identify these and assess
relevant retraction statements and errata for included
trials.
Data collection and analysis
We will perform and report the review following the rec-
ommendations stated in the Cochrane Handbook for
Systematic Reviews of Interventions [36]. Analyses will
be performed using Stata version 16.1 (StataCorp LLC,
College Station, TX, USA) [51] and Trial Sequential
Analysis [52, 53].
Selection of studies
Two review authors will independently screen titles and
abstracts. We will retrieve all relevant full-text study re-
ports/publications, and two review authors will inde-
pendently screen the full text and identify and record
reasons for exclusion of the ineligible studies. The two
review authors will resolve any disagreement through
discussion, or, if required, they will consult a third
author.
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Data extraction and management
Two authors will independently extract data from in-
cluded trials in a dedicated data extraction sheet devel-
oped for this review. Disagreements will be resolved by
discussion with a third author. The two review authors
will assess duplicate publications and companion papers
of a trial together to evaluate all available data simultan-
eously (maximise data extraction, correct bias assess-
ment). We will contact the trial authors by email to
specify any additional data, which may not have been re-
ported sufficiently or at all in the publication.
Trial characteristics
We will extract the following data: bias risk components
(as defined below), trial design (parallel, factorial, or
crossover), number of intervention groups, length of
follow-up, estimation of sample size, and inclusion and
exclusion criteria.
Participant characteristics
We will extract the following data: number of rando-
mised participants, number of analysed participants,
number of participants lost to follow-up/withdrawals/
crossover, age range (mean or median), and sex ratio.
Intervention characteristics
We will extract the following data: type of antidepres-
sant, dose of intervention, and duration of intervention.
Control characteristics
We will extract the following data: type of control inter-
vention, dose of intervention, and duration of
intervention.
Outcomes
All outcomes listed above will be extracted from each
randomised clinical trial, and we will identify if out-
comes are incomplete or selectively reported according
to the criteria described later in ‘incomplete outcome
data’ bias domain and ‘selective outcome reporting’ bias
domain.
Notes
We will search for information regarding industry fund-
ing of either personal or academic activities for each trial
author. We will judge a publication at high risk of for-
profit bias if a trial is sponsored by the industry or if just
one author has affiliation to the industry. We will note
in the ‘Characteristics of included studies’ table, if out-
come data were not reported in a usable way. Two re-
view authors will independently transfer data into the
Stata file [51]. Disagreements will be resolved through
discussion, or if required, we will consult with a third
author.
Assessment of risk of bias in the included trials
Our bias risk assessment will be based on the Cochrane
Risk of Bias tool-version 2 (RoB 2) as recommended in
The Cochrane Handbook of Systematic Reviews of Inter-
ventions [36]. We will evaluate the methodology in re-
spect of the following bias domains:
Bias arising from the randomisation process
 Low risk of bias. Allocation was adequately
concealed, AND there are no baseline imbalances
across intervention groups at baseline appear to be
compatible with chance, AND an adequate (random
or otherwise unpredictable) method was used to
generate allocation sequence, OR there is no
information about the method used to generate the
allocation sequence.
 Some concerns. Allocation was adequately concealed,
AND there is a problem with the method of
sequence generation, OR baseline imbalances
suggest a problem with the randomisation process,
OR no information is provided about concealment
of allocation, AND baseline imbalances across
intervention groups appear to be compatible with
chance, OR no information to answer any of the
signalling questions,
 High risk of bias. Allocation sequence was not
concealed, OR no information is provided about
concealment of allocation sequence, AND baseline
imbalances suggest a problem with the
randomisation process.
Bias due to deviation from intended interventions
 Low risk of bias. Participants, carers, and personnel
were unaware of intervention groups during the
trial, OR participants, carers, or personnel were
aware of intervention groups during the trial but any
deviations from intended intervention reflected
usual practice, OR participants, carers, or personnel
were aware of intervention groups during the trial
but any deviations from intended intervention were
unlikely to impact on the outcome, AND no
participants were analysed in the wrong intervention
groups (that is, on the basis of intervention actually
received rather than of randomised allocation).
 Some concerns. Participants, carers, or personnel
were aware of intervention groups and there is no
information on whether there were deviations from
usual practice that were likely to impact on the
outcome and were imbalanced between intervention
groups, OR some participants were analysed in the
wrong intervention groups (on the basis of
intervention actually received rather than of
Juul et al. Systematic Reviews          (2021) 10:154 Page 6 of 13
randomised allocation) but there was little potential
for a substantial impact on the estimated effect of
intervention.
 High risk of bias. Participants, carers, or personnel
were aware of intervention groups, and there were
deviations from intended interventions that were
unbalanced between the intervention groups and
likely to have affected the outcome, OR some
participants were analysed in the wrong intervention
groups (on the basis of intervention actually received
rather than of randomised allocation), and there was
potential for a substantial impact on the estimated
effect of intervention.
Bias due to missing outcome data
 Low risk of bias. No missing data OR non-
differential missing data (similar proportion of and
similar reasons for missing data in compared groups)
OR evidence of robustness of effect estimate to
missing data (based on adequate statistical methods
for handling missing data and sensitivity analysis)
 Some concerns. An unclear degree of missing data or
unclear information on proportion and reasons for
missingness in compared groups AND there is no
evidence that the effect estimate is robust to missing
data
 High risk of bias. A high degree of missing data
AND differential missing data (different proportion
of or different reasons for missing data in compared
groups) AND there is no evidence that the effect
estimate is robust to missing data
Bias in measurement of outcomes
 Low risk of bias. The outcome assessors were
unaware of the intervention received by study
participants, OR the outcome assessors were aware
of the intervention received by study participants,
but the assessment of the outcome was unlikely to
be influenced by knowledge of the intervention
received.
 Some concerns. There is no information available to
determine whether the assessment of the outcome is
likely to be influenced by knowledge of the
intervention received.
 High risk of bias. The assessment of the outcome
was likely to be influenced by knowledge of the
intervention received by study participants.
Bias arising from selective reporting of results
 Low risk of bias. Reported outcome data are unlikely
to have been selected, on the basis of the results,
from multiple outcome measurements (e.g. scales,
definitions, time points) within the outcome domain,
and reported outcome data are unlikely to have been
selected, on the basis of the results, from multiple
analyses of the data.
 Some concerns. There is insufficient information
available to exclude the possibility that reported
outcome data were selected, on the basis of the
results, from multiple outcome measurements (e.g.
scales, definitions, time points) within the outcome
domain, or from multiple analyses of the data. Given
that analysis intentions are often unavailable or not
reported with sufficient detail, we anticipate that this
will be the default judgement for most trials.
 High risk of bias. Reported outcome data are likely
to have been selected, on the basis of the results,
from multiple outcome measurements (e.g. scales,
definitions, time points) within the outcome domain,
or from multiple analyses of the data (or both).
Overall assessment of risk of bias
 Low risk of bias. The trial is judged to be at low risk
of bias for all domains.
 High risk of bias. The trial is judged to be at high
risk of bias or to be at some concerns in at least one
domain. Our subgroup analysis will compare the
intervention effect of trials at low risk of bias with
trials at high risk of bias, that is one or more
domains at some concern or high risk of bias.
We will assess the domains ‘missing outcome data’,
‘risk of bias in measurement of the outcome’, and ‘risk
of bias in selection of the reported result’ for each out-
come result. Thus, we can assess the bias risk for each
outcome assessed in addition to each trial. Our primary
conclusions will be based on the results of our primary
outcome results with overall low risk of bias. Both our
primary and secondary conclusions will be presented in
the ‘Summary of findings’ tables.
Differences between the protocol and the review
We will conduct the review according to this published
protocol and report any deviations from it in the ‘Differ-
ences between the protocol and the review’ section of
the systematic review.
Measurement of treatment effect
Dichotomous outcomes We will calculate risk ratios
(RRs) with 95% confidence interval (CI) for dichotomous
outcomes, as well as the Trial Sequential Analysis-
adjusted CIs (see the following).
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Continuous outcomes We will calculate the mean dif-
ferences (MDs) and consider calculating the standar-
dised mean difference (SMD) with 95% CI for
continuous outcomes. We will also calculate Trial Se-
quential Analysis-adjusted CIs (see the following).
Dealing with missing data
We will use intention-to-treat data if provided by the tri-
alists [54]. We will, as the first option, contact all trial
authors to obtain any relevant missing data (i.e. for data
extraction and for assessment of risk of bias, as specified
above).
Dichotomous outcomes We will not impute missing
values for any outcomes in our primary analysis. In our
sensitivity analyses (see the following paragraph), we will
impute data.
Continuous outcomes We will primarily analyse scores
assessed at single time points. If only changes from base-
line scores are reported, we will analyse the results to-
gether with follow-up scores [36]. If standard deviations
(SDs) are not reported, we will calculate the SDs using
trial data, if possible. We will not use intention-to-treat
data if the original report did not contain such data. We
will not impute missing values for any outcomes in our
primary analysis. In our sensitivity analysis (see the fol-
lowing paragraph) for continuous outcomes, we will im-
pute data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually as-
sess any sign of heterogeneity. We will secondly assess
the presence of statistical heterogeneity by chi2 test
(threshold P < 0.10) and measure the quantities of het-
erogeneity by the I2 statistic [55, 56]. We will investigate
possible heterogeneity through subgroup analyses. We
may ultimately decide that a meta-analysis should be
avoided [36].
Assessment of reporting biases
We will use a funnel plot to assess reporting bias if ten
or more trials are included. We will visually inspect fun-
nel plots to assess the risk of bias. We are aware of the
limitations of a funnel plot (i.e. a funnel plot assesses
bias due to small sample size). From this information,
we assess possible reporting bias. For dichotomous out-
comes, we will test asymmetry with the Harbord test
[57] if τ2 is less than 0.1 and with the Rücker test if τ2 is
more than 0.1. For continuous outcomes, we will use the
regression asymmetry test [58] and the adjusted rank
correlation [59].
Unit of analysis issues
We will only include randomised clinical trials. For trials
using crossover design, only data from the first period
will be included [36, 60]. There will therefore not be any
unit of analysis issues. We will not include cluster-
randomised trials, due to their problems with random-
isation, and blinding.
Data synthesis
Meta-analysis We will undertake the meta-analysis
according to The Cochrane Handbook for Systematic
Reviews of Interventions [36], Keus et al. [61], and
our eight-step procedure suggested by Jakobsen et al.
[62]. We will use the statistical software Stata ver-
sion 16 to analyse data [51]. We will assess our
intervention effects with both random-effects model
meta-analyses (Hartung-Knapp-Sidik-Jonkman) [63]
and fixed-effect model meta-analyses (Mantel-Haens-
zel for dichotomous outcomes and inverse variance
for continuous outcomes) [36, 64]. We will use the
more conservative point estimate of the two [62].
The more conservative point estimate is the estimate
with the highest p-value. We assess a total of six
primary and secondary outcomes, and we will there-
fore consider a p-value of 0.014 or less as the
threshold for statistical significance [62]. We will in-
vestigate possible heterogeneity through subgroup
analyses. We will use our eight-step procedure to as-
sess if the thresholds for significance are crossed
[62]. This eight-step procedure comprise of the fol-
lowing steps: (1) obtain the 95% confidence intervals
and the P-values from both fixed-effect and random-
effects meta-analyses and report the most conserva-
tive results as the main results, (2) explore the rea-
sons behind substantial statistical heterogeneity using
subgroup and sensitivity analyses (see step 6), (3) to
take account of problems with multiplicity adjust the
thresholds for significance according to the number
of primary outcomes (we will both adjust the thresh-
olds for significance according to the number of pri-
mary and secondary outcomes), (4) calculate
required information sizes (≈ the a priori required
number of participants for a meta-analysis to be
conclusive) for all outcomes and analyse each out-
come with trial sequential analysis. Report whether
the trial sequential monitoring boundaries for bene-
fit, harm, or futility are crossed, (5) calculate Bayes
factors for all primary outcomes, (6) use subgroup
analyses and sensitivity analyses to assess the poten-
tial impact of bias on the review results, (7) assess
the risk of publication bias, and (8) assess the clin-
ical significance of the statistically significant review
results [62].
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Where multiple trial arms are reported in a single trial,
we will include only the relevant arms. If two compari-
sons are combined in the same meta-analysis, we will
halve the control group (participants and amount of
evens to avoid double-counting). For continuous data,
we will keep the main score [36]. Trials with a factorial
design will be included. In case of, e.g. a 2 × 2 factorial
designed trial, the two groups receiving antidepressants
will be considered experimental groups, while the two
groups receiving placebo, ‘active placebo’, or no inter-
vention will be considered control groups.
Trial Sequential Analysis Traditional meta-analysis
runs the risk of random errors due to sparse data and
repetitive testing of accumulating data when updating
reviews. We wish to control the risks of type I errors
and type II errors. We will therefore perform Trial Se-
quential Analysis on all outcomes, in order to calculate
the diversity-adjusted required information size (DARIS;
that is, the number of participants needed in a meta-
analysis to detect or reject a certain intervention effect)
and the cumulative Z-curve’s breach of relevant trial se-
quential monitoring boundaries [52, 53, 65–71]. A more
detailed description of Trial Sequential Analysis software
can be found in the manual [53] and at http://www.ctu.
dk/tsa/. For dichotomous outcomes, we will estimate the
required information size based on the observed propor-
tion of patients with an outcome in the control group
(the cumulative proportion of patients with an event in
the control groups relative to all patients in the control
groups), a relative risk reduction or a relative risk in-
crease of 20%, an alpha of 1.6% for all our outcomes, a
beta of 10%, and the observed diversity as suggested by
the trials in the meta-analysis. For continuous outcomes,
we will in the Trial Sequential Analysis use the observed
standard deviation (SD) in the control group, a mean
difference of three HDRS points when assessing depres-
sive symptoms (for other continuous outcomes the ob-
served SD/2), an alpha of 1.6% for all outcomes, a beta
of 10%, and the observed diversity as suggested by the
trials in the meta-analysis.
Subgroup analysis and integration of heterogeneity
Subgroup analysis We will perform the following sub-
group analyses when analysing the primary outcomes
(depressive symptoms, serious adverse events, quality of
life).
1. Trials at high risk of bias compared to trials at low
risk of bias
2. Trials with for-profit bias compared to trials at un-
known or known risk of for-profit bias [72]
3. Types of antidepressant drug
4. Types of comparator (placebo, ‘active placebo’, no
intervention)
5. Age groups (18 to 24 years, 25 to 64 years, ≥ 65
years)
We will use the formal test for subgroup interactions
in Stata [51].
Sensitivity analysis To assess the potential impact of
the missing data for dichotomous outcomes, we will per-
form the two following sensitivity analyses on both the
primary and secondary dichotomous outcomes.
 ‘Best-worst-case’ scenario. We will assume that all
participants lost to follow-up in the antidepressant
group survived, had no serious adverse events, had
no suicides or suicide attempts, and had no non-
serious adverse events, and that all those participants
lost to follow-up in the control group did not sur-
vive, had a serious adverse event, died by suicide or
had a suicide attempt, and had a non-serious adverse
event.
 ‘Worst-best-case’ scenario. We will assume that all
participants lost to follow-up in the antidepressant
group did not survive, had a serious adverse event,
died by suicide or had a suicide attempt, and had a
non-serious adverse event, and that all those partici-
pants lost to follow-up in the control group sur-
vived, had no serious adverse events, had no suicides
or suicide attempts, and had no non-serious adverse
events.
We will present results of both scenarios in our re-
view. When analysing depressive symptoms, suicidal
ideation, and quality of life, a ‘beneficial outcome’ will be
the group mean plus two SDs (we will secondly use one
SD in another sensitivity analysis) of the group mean
and a ‘harmful outcome’ will be the group mean minus
two SDs (we will secondly use one SD in another sensi-
tivity analysis) of the group mean [62]. To assess the po-
tential impact of missing SDs for continuous outcomes,
we will perform the following sensitivity analysis:
 Where SDs are missing and it is not possible to
calculate them, we will impute SDs from trials with
similar populations and low risk of bias. If we find
no such trials, we will impute SDs from trials with a
similar population. As the final option, we will
impute the mean SD from all included trials.
We will present results of this scenario in our review.
Other post hoc sensitivity analyses might be warranted if
unexpected clinical or statistical heterogeneity is identi-
fied during the analysis of the review results [62].
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‘Summary of findings’ tables We will create summary
of findings tables for each comparison including each of
the prespecified primary and secondary outcomes (de-
pressive symptoms, serious adverse events, quality of life,
suicide or suicide attempt, non-serious adverse events).
We will use the five Grading Recommendations Assess-
ment Development Evaluation (GRADE) considerations
(bias risk, heterogeneity, imprecision, indirectness, and
publication bias) to assess the certainty of evidence [62,
73–75]. We will assess imprecision using Trial Sequen-
tial Analysis. We will downgrade imprecision in GRADE
by two levels if the accrued number of participants is
below 50% of the DARIS, and one level if between 50
and 100% of DARIS. We will not downgrade if the cu-
mulative Z-curve crosses the monitoring boundaries for
benefit, harm, or futility, or if DARIS is reached. We will
justify all decisions to downgrade the quality of evidence
using footnotes, and we will make comments to aid the
reader’s understanding of the assessment where neces-
sary. Firstly, we will present our results in the summary
of findings tables based on the results from the trials
with overall low risk of bias, and secondly, we will
present the results based on all trials.
Project plan
We will publish separate systematic reviews assessing
the beneficial and harmful effects of the most frequently
used antidepressants. We will subsequently gather data
from all these reviews, update the searches and analyses,
and finally publish the overall results from all antide-
pressants in a large publication. We will publish the fol-
lowing protocols and systematic reviews separately: (1)
tricyclic antidepressants, (2) SSRIs, (3) venlaflaxine, (4)
mirtazapine, and (5) duloxetine.
Discussion
This protocol aims at assessing the beneficial and harm-
ful effects of antidepressants versus placebo, ‘active pla-
cebo’, or no intervention in adults with major depressive
disorder. Primary outcomes will be depressive symp-
toms, serious adverse events, and quality of life. Second-
ary outcomes will be suicide or suicide attempts, suicidal
ideation, and non-serious adverse events.
Our protocol has a number of strengths. The prede-
fined methodology is based on Cochrane methodology
[36], PRISMA [76, 77], Keus et al. [61], our eight-step
assessment suggested by Jakobsen et al. [62], Trial Se-
quential Analysis [52], and GRADE assessment [73–75].
Hence, this protocol considers both risks of random er-
rors and risks of systematic errors [62]. Further, we in-
crease the statistical power by pooling various
antidepressants as the experimental intervention. More-
over, we will include both unpublished and published
trials as well as clinical study reports [50].
Our protocol also has limitations. The primary limita-
tion is the potential for high statistical heterogeneity as a
result of including various antidepressants as the experi-
mental intervention. To minimise this limitation, we will
carefully look for signs of heterogeneity and ultimately
decide if data ought to be pooled and meta-analysed,
and we have planned several subgroup analyses. Another
limitation is the large number of analyses which in-
creases the risk of type 1 error. We have adjusted our
thresholds for significance according to the number of
primary and secondary outcomes, but we have not ad-
justed our thresholds for significance according to the
total number of comparisons (e.g. subgroup analyses and
sensitivity analyses). As mentioned in the ‘Background’
section, we expect inadequate reporting of harmful ef-
fects in the included trials, which increases the risk of
underestimation of harmful effects. Finally, we expect
short follow-up periods.
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